Alerts will be sent to your verified email
Verify EmailNATCOPHARM
|
Natco Pharma
|
Astrazeneca Pharma I
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
51.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
41.0 . | n/a | n/a |
|
Domestic Sales Growth - YoY
|
31.2 % | 18.6 % | 11.8 % |
|
US DMF Filings
|
58.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
9.1 % | 0.0 | 0.0 |
|
Financials
|
|||
|
5 yr Average ROE
|
15.58 % | 17.42 % | 17.74 % |
|
5yr average Equity Multiplier
|
1.17 | 1.99 | 1.76 |
|
5yr Average Asset Turnover Ratio
|
0.48 | 0.91 | 0.51 |
|
5yr Avg Net Profit Margin
|
26.79 % | 9.65 % | 22.76 % |
|
Price to Book
|
2.26 | 26.22 | 5.9 |
|
P/E
|
12.58 | 104.3 | 42.21 |
|
5yr Avg Cash Conversion Cycle
|
4.27 Days | -6.33 Days | -54.68 Days |
|
Inventory Days
|
91.91 Days | 68.19 Days | 27.48 Days |
|
Days Receivable
|
93.3 Days | 35.81 Days | 54.07 Days |
|
Days Payable
|
134.54 Days | 187.52 Days | 148.48 Days |
|
5yr Average Interest Coverage Ratio
|
60.49 | 142.38 | 66.44 |
|
5yr Avg ROCE
|
19.09 % | 23.84 % | 18.34 % |
|
5yr Avg Operating Profit Margin
|
34.0 % | 14.57 % | 34.43 % |
|
5 yr average Debt to Equity
|
0.06 | 0.0 | 0.46 |
|
5yr CAGR Net Profit
|
33.73 % | 4.4 % | -0.19 % |
|
5yr Average Return on Assets
|
13.46 % | 8.92 % | 12.4 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
49.42 % | 75.0 % | 53.92 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 16.92 % |
|
Change in Promoter Holding (3 Yrs)
|
0.58 % | 0.0 | 1.06 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-6.78 % | 4.44 % | 8.58 % |
|
Natco Pharma
|
Astrazeneca Pharma I
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|